SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Rubius Therapeutics Q1 EPS $(0.60) Misses $(0.55) Estimate

Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.600) per share which missed the analyst consensus estimate of $(0.550) by 9.09 percent. This is a 42.86 percent decrease over losses of $(0.420) per

Benzinga · 05/11/2020 12:11

Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.600) per share which missed the analyst consensus estimate of $(0.550) by 9.09 percent. This is a 42.86 percent decrease over losses of $(0.420) per share from the same period last year.